In models that controlled for CUD, the schizophrenia PRS was significantly associated with all cannabis-related experiences (maximum P < 6.8e−4) except hallucinations (P = .47; figure 1; table 4). The association between the schizophrenia PRS and reporting any cannabis-related experience did not pass our statistical significance threshold (P = .001), but the schizophrenia PRS was associated with endorsing a greater number of cannabis-related experiences (meta-analysis beta = 0.11, P = 1.3e−6). Associations between the schizophrenia PRS and paranoia and depression/anhedonia were weaker in the African ancestry (AA) sample of COGA (betas = 0.03–0.04, SEs = 0.07–0.08) than in the European ancestry (EA) sample (betas = 0.24–0.25, SEs = 0.06), with significant heterogeneity in the meta-analysis. Across both ancestries, cognitive difficulties after cannabis use were most robustly associated with the schizophrenia PRS (AA beta = 0.14 [SE = 0.07]; EA beta = 0.27 [SE = 0.06]; meta-analysis beta = 0.22, P = 5.2e−7). The schizophrenia PRS was not significantly associated with the use of other illicit substances (meta-analyzed beta = 0.027, P = .57).
